Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $6,000 | 3 | 67.2% |
| Consulting Fee | $1,620 | 1 | 18.1% |
| Food and Beverage | $1,314 | 17 | 14.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alimera Sciences, Inc. | $6,629 | 11 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $1,620 | 1 | $0 (2022) |
| Allergan, Inc. | $669.86 | 8 | $0 (2021) |
| Smith & Nephew, Inc. | $15.83 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140.00 | 1 | Alimera Sciences, Inc. ($140.00) |
| 2022 | $6,712 | 5 | Alimera Sciences, Inc. ($5,092) |
| 2021 | $104.16 | 1 | Allergan, Inc. ($104.16) |
| 2019 | $1,263 | 5 | Alimera Sciences, Inc. ($1,147) |
| 2018 | $232.37 | 4 | Allergan Inc. ($216.54) |
| 2017 | $483.88 | 5 | Alimera Sciences, Inc. ($250.00) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/24/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/13/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $41.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/10/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/07/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $50.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/05/2022 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/01/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 05/19/2021 | Allergan, Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $104.16 | General |
| Category: RETINA | ||||||
| 10/23/2019 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $115.28 | General |
| Category: RETINA | ||||||
| 10/12/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 10/12/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $85.44 | General |
| Category: Ophthalmology | ||||||
| 10/12/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $42.45 | General |
| Category: Ophthalmology | ||||||
| 10/11/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $19.33 | General |
| Category: Ophthalmology | ||||||
| 10/24/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: RETINA | ||||||
| 02/22/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $74.87 | General |
| Category: RETINA | ||||||
| 02/22/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $41.67 | General |
| Category: RETINA | ||||||
| 02/21/2018 | Smith & Nephew, Inc. | PICO (Device) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Negative Pressure Wound Therapy | ||||||
| 11/11/2017 | Alimera Sciences, Inc. | Iluvien (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Ophthalmology | ||||||
| 10/05/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: RETINA | ||||||
| 08/31/2017 | Alimera Sciences, Inc. | Iluvien (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Opthalmology | ||||||
| 08/17/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: RETINA | ||||||
| 08/17/2017 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: RETINA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 34 | 48 | $7,774 | $3,042 |
| 2022 | 3 | 79 | 111 | $13,284 | $6,947 |
| 2021 | 3 | 72 | 105 | $12,538 | $6,347 |
| 2020 | 3 | 77 | 110 | $13,739 | $5,476 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 48 | $7,774 | $3,042 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 41 | 63 | $8,820 | $5,074 | 57.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 26 | 31 | $2,883 | $1,515 | 52.6% |
| 92134 | Imaging of retina | Facility | 2022 | 12 | 17 | $1,581 | $357.01 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 59 | $8,260 | $4,579 | 55.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 26 | $2,418 | $1,381 | 57.1% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 14 | 20 | $1,860 | $387.36 | 20.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 49 | 72 | $10,205 | $4,417 | 43.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 16 | $1,488 | $620.23 | 41.7% |
| 92134 | Diagnostic imaging of retina | Facility | 2020 | 15 | 22 | $2,046 | $438.84 | 21.4% |
About Dr. Nirali Bhatt, MD
Dr. Nirali Bhatt, MD is a Ophthalmology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2009. The National Provider Identifier (NPI) number assigned to this provider is 1174758791.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nirali Bhatt, MD has received a total of $8,934 in payments from pharmaceutical and medical device companies, with $140.00 received in 2024. These payments were reported across 21 transactions from 4 companies. The most common payment nature is "Honoraria" ($6,000).
As a Medicare-enrolled provider, Bhatt has provided services to 262 Medicare beneficiaries, totaling 374 services with total Medicare billing of $21,812. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Other Specialties Uveitis and Ocular Inflammatory Disease
- Location Philadelphia, PA
- Active Since 05/27/2009
- Last Updated 04/11/2018
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1174758791
Products in Payments
- ILUVIEN (Drug) $5,092
- YUTIQ (Drug) $1,760
- Iluvien (Drug) $1,147
- OZURDEX (Drug) $669.86
- Iluvien (Biological) $250.00
- PICO (Device) $15.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Philadelphia
Robert Sergott, Md, MD
Ophthalmology — Payments: $1.7M
Mark Blecher, Md, MD
Ophthalmology — Payments: $591,672
Dr. Joshua Greene, Md, MD
Ophthalmology — Payments: $488,392
Joseph Markoff, Md Phd, MD PHD
Ophthalmology — Payments: $441,634
Dr. Jonathan Myers, M.d, M.D
Ophthalmology — Payments: $412,982
Beeran Meghpara, M.d, M.D
Ophthalmology — Payments: $330,295